Limits...
Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants.

Radojkovic J, Sikanic N, Bukumiric Z, Tadic M, Kostic N, Babic R - Med. Sci. Monit. (2016)

Bottom Line: BDI-II scores improved significantly from 30.4±13.2 to 23.5±11.0 (p=0.02) during the interventional phase.Lipid profile and inflammatory status did not change significantly during the interventional phase.This therapy did not have any adverse effects on lipid profile or inflammatory status.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Endocrinology, Clinical Center "Dr Dragisa Misovic", Belgrade, Serbia.

ABSTRACT
BACKGROUND It is still disputable whether negative effects of comorbid depression in diabetics can be diminished by successful treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin treatment would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status. MATERIAL AND METHODS Total of 192 patients with poorly controlled diabetes (defined as HbA1c ≥8%) in the absence of any uncontrolled medical condition entered the 6-month run-in phase with optimization of diabetic therapy. Depression status was screened at the end of this phase by BDI-II depression testing. Patients with BDI-II ≥14 and psychiatric confirmation of depression (58 patients) entered the 6-month interventional phase with SSRI class antidepressants. RESULTS Fifty patients completed the study. During the run-in phase, HbA1c dropped from 10.0±1.8% to 8.5±1.2% (p<0.001), and during the interventional phase it dropped from 8.5±1.2% to 7.7±0.7% (p<0.001). BDI-II scores improved significantly from 30.4±13.2 to 23.5±11.0 (p=0.02) during the interventional phase. A positive linear correlation between improvement in depression scale and improvement in glycemic control was observed (R²=0.139, p=0.008). Lipid profile and inflammatory status did not change significantly during the interventional phase. CONCLUSIONS Patients with poorly controlled diabetes and comorbid depression might benefit from screening and treatment of depression with SSRI antidepressants by achieving an incremental effect on glycoregulation. This therapy did not have any adverse effects on lipid profile or inflammatory status.

No MeSH data available.


Related in: MedlinePlus

Interventional effect of antidepressants on depression scale.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4920101&req=5

f3-medscimonit-22-2133: Interventional effect of antidepressants on depression scale.

Mentions: Improvement in depression status by antidepressants therapy was confirmed by the significant decrease of BDI-II scores from 30.4±13.2 to 23.5±11.0 (p=0.02) over the interventional phase. This direct and sustained effect of antidepressants on depression is presented in Figure 3. The observed reduction in DBI-II score of 6.9 represents a clinically meaningful improvement of depression status in study patients [28].


Improvement of Glycemic Control in Insulin-Dependent Diabetics with Depression by Concomitant Treatment with Antidepressants.

Radojkovic J, Sikanic N, Bukumiric Z, Tadic M, Kostic N, Babic R - Med. Sci. Monit. (2016)

Interventional effect of antidepressants on depression scale.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4920101&req=5

f3-medscimonit-22-2133: Interventional effect of antidepressants on depression scale.
Mentions: Improvement in depression status by antidepressants therapy was confirmed by the significant decrease of BDI-II scores from 30.4±13.2 to 23.5±11.0 (p=0.02) over the interventional phase. This direct and sustained effect of antidepressants on depression is presented in Figure 3. The observed reduction in DBI-II score of 6.9 represents a clinically meaningful improvement of depression status in study patients [28].

Bottom Line: BDI-II scores improved significantly from 30.4±13.2 to 23.5±11.0 (p=0.02) during the interventional phase.Lipid profile and inflammatory status did not change significantly during the interventional phase.This therapy did not have any adverse effects on lipid profile or inflammatory status.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Endocrinology, Clinical Center "Dr Dragisa Misovic", Belgrade, Serbia.

ABSTRACT
BACKGROUND It is still disputable whether negative effects of comorbid depression in diabetics can be diminished by successful treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin treatment would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status. MATERIAL AND METHODS Total of 192 patients with poorly controlled diabetes (defined as HbA1c ≥8%) in the absence of any uncontrolled medical condition entered the 6-month run-in phase with optimization of diabetic therapy. Depression status was screened at the end of this phase by BDI-II depression testing. Patients with BDI-II ≥14 and psychiatric confirmation of depression (58 patients) entered the 6-month interventional phase with SSRI class antidepressants. RESULTS Fifty patients completed the study. During the run-in phase, HbA1c dropped from 10.0±1.8% to 8.5±1.2% (p<0.001), and during the interventional phase it dropped from 8.5±1.2% to 7.7±0.7% (p<0.001). BDI-II scores improved significantly from 30.4±13.2 to 23.5±11.0 (p=0.02) during the interventional phase. A positive linear correlation between improvement in depression scale and improvement in glycemic control was observed (R²=0.139, p=0.008). Lipid profile and inflammatory status did not change significantly during the interventional phase. CONCLUSIONS Patients with poorly controlled diabetes and comorbid depression might benefit from screening and treatment of depression with SSRI antidepressants by achieving an incremental effect on glycoregulation. This therapy did not have any adverse effects on lipid profile or inflammatory status.

No MeSH data available.


Related in: MedlinePlus